The tau pathway is the focus of a new investment by Bristol-Myers Squibb Company which is planning to spend $175 million in cash and potential milestones of $550 million to acquire the privately-owned biotechnology company iPierian Inc. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
